Astrin Biosciences shared a post on LinkedIn::
“Introducing Certitude. The first ever non-imaging blood test for breast cancer.
Certitude Breast is a first-of-its-kind, non-imaging, blood-based early cancer detection test based in deep proteomics and AI. For the nearly 50% of women with dense breast tissue, routine screening can be a journey of anxiety and uncertainty, often leading to false positives and unnecessary invasive procedures.
We knew there had to be a another way.
Next week, at the San Antonio Breast Cancer Symposium, we are proud to present our early findings for a deeper look into the science behind Certitude.
This is a pivotal moment in our mission to make early cancer detection simple, accurate, and accessible. Certitude Breast will be available in the U.S. in early 2026 by prescription only. To learn more, drop by booth 1328 at hashtag#SABCS next week.
Adrian Lee, Director of the Institute for Precision Medicine at UPMC and Professor at the University of Pittsburgh, shared Astrin Biosciences’s post on LinkedIn, adding:
“Sharing an important milestone in breast cancer screening from Astrin Biosciences
This week, the company announced the launch of Certitude Breast, the first non-imaging, blood-based test designed to detect breast cancer.
In a study including 1,242 women, Certitude demonstrated:
- 92% sensitivity
- 93% specificity
- 99.9% negative predictive value
Importantly, these results were consistent across cancer stages, molecular subtypes, and demographic groups.
This represents a meaningful development, particularly for individuals with dense breast tissue, where traditional imaging can be less effective and often leads to uncertainty or delayed diagnosis.
The supporting data will be presented at the San Antonio Breast Cancer Symposium (SABCS), advancing ongoing efforts to advance early detection strategies and improve outcomes.
Congratulations to the Astrin team and partners involved in bringing this innovation forward.”
More posts featuring Adrian Lee.